ReviewCureus2019
A Review of Novel Antidepressants: A Guide for Clinicians.
Review in Cureus, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Chinese herbal medicines for the treatment of depression: a systematic review and network meta-analysis.Frontiers in pharmacology · 2024Pooled it
- Effectiveness and Safety of Ketamine for Unipolar Depression: a Systematic Review.The Psychiatric quarterly · 2020Pooled it
- Understanding Target-Specific Effects of Antidepressant Drug Pollution on Molluscs: A Systematic Review Report.Toxics · 2025Review
- Short-Term Irisin Treatment Enhanced Neurotrophin Expression Differently in the Hippocampus and the Prefrontal Cortex of Young Mice.International journal of molecular sciences · 2023Article
- Recent Developments in Pharmacotherapy of Depression: Bench to Bedside.Journal of personalized medicine · 2023Review
- The Sympathetic Nervous System in Dental Implantology.Journal of clinical medicine · 2023Review
- Global Advancement in Pharmacy Services for Mental Health: A Review for Evidence-Based Practices.Healthcare (Basel, Switzerland) · 2023Review
- Depression and Its Phytopharmacotherapy-A Narrative Review.International journal of molecular sciences · 2023Review
- Nanoencapsulation ofPharmaceuticals (Basel, Switzerland) · 2023Article
- The use of antidepressants is linked to bone loss: A systematic review and metanalysis.Orthopedic reviews · 2022Article
- Is depression the contraindication of anterior cervical decompression and fusion for cervical spondylosis?Frontiers in endocrinology · 2022Article
- Design Strategies, Chemistry and Therapeutic Insights of Multi-target Directed Ligands as Antidepressant Agents.Current neuropharmacology · 2022Article
- Involvement of oxidative pathways and BDNF in the antidepressant effect of carvedilol in a depression model induced by chronic unpredictable stress.Psychopharmacology · 2022Article
- Off-label Uses of Selective Serotonin Reuptake Inhibitors (SSRIs).Current neuropharmacology · 2022Review
- AMELIORATIVE EFFECT OF VORTIOXETINE IN EXPERIMENTAL MODEL OF ENDOCRINE PANCREAS DAMAGE RELATED TO CHRONIC UNPREDICTABLE MILD STRESS: AN IMMUNOHISTOCHEMICAL STUDY.Acta endocrinologica (Bucharest, Romania : 2005)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review article aims to provide insight into the mechanisms of action, pharmacokinetics, clinical efficacy, safety and tolerability of four novel antidepressants including desvenlafaxine, vortioxetine, vilazodone, and levomilnacipran. Following keywords are used in PubMed and Scopus to search for relevant articles: (depression) AND (psychopharmacology OR desvenlafaxine OR levomilnacipran OR vortioxetine OR vilazodone). Patients with a lack of effectiveness or tolerability to certain antidepressants may get benefit from selecting a new antidepressant with different mechanism of action. These medications can be an option in the selection of newer antidepressants. Depression may not be caused by the simple deficiency of serotonin in the brain, but rather a complex interplay of various neurotransmitters including serotonin, norepinephrine, glutamate, and histamine at certain brain areas. The above-mentioned novel antidepressants exert their therapeutic benefits by acting on multiple neurotransmitters. The complexity of underlying the neurobiological mechanism should be considered while formulating a plan of care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.